Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals

Clinical Chemistry

Volumn 52, Issue 8, 2006, Pages 1546-1551

  Slagter, Margrita H ^a   Scorilas, Andreas ^b   Gooren, Louis J G ^a   De Ronde, Willem ^a   Soosaipillai, Antoninus ^c   Giltay, Erik J ^d   Paliouras, Miltiadis ^c,e   Diamandis, Eleftherios P ^c,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ATHENS   (Greece)

^c MOUNT SINAI HOSPITAL   (Canada)

^d GGZ Delfland   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HUMAN TISSUE KALLIKREIN 10; HUMAN TISSUE KALLIKREIN 11; HUMAN TISSUE KALLIKREIN 13; HUMAN TISSUE KALLIKREIN 14; HUMAN TISSUE KALLIKREIN 2; HUMAN TISSUE KALLIKREIN 3; HUMAN TISSUE KALLIKREIN 4; HUMAN TISSUE KALLIKREIN 5; HUMAN TISSUE KALLIKREIN 6; HUMAN TISSUE KALLIKREIN 7; HUMAN TISSUE KALLIKREIN 8; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; KALLIKREIN URINE LEVEL; TESTOSTERONE BLOOD LEVEL; TRANSSEXUALISM; URINALYSIS;

ADOLESCENT; ADULT; ANDROGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KALLIKREINS; MALE; TESTOSTERONE; TRANSSEXUALISM;

EID: 33746613205     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.067041     Document Type: Article

References (37)

1. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
2. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family: a novel panel of cancer biomarkers. Tumour Biol 2002;23:185-92.
3. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005;224:1-22.
4. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
5. Yousef GM, Diamandis EP. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48:1198-205.
6. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJG, Yu H, et al. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. Clin Chem 2000;46:859-62.
7. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, et al. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by anti-androgens in male-to-female transsexuals. J Urol 2000;163:802-5.
8. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 1999;45:790-9.
9. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996;42:675-84.
10. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunoflurometry and immunohistochemistry. Clin Chem 2002;48:1232-40.
11. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63: 3958-65.
12. Diamandis EP, Scorials A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
13. Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, Diamandis EP. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem 2004;50:709-16.
14. Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP. Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 2003;49:87-96.
15. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001;47:237-46.
16. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
17. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 2003;49:77-86.
18. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-41.
19. Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 2000;85:81-4.
20. Bahceci M, Bilge M, Tuzcu A, Tuzcu S, Bahceci S. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination. J Endocrinol Invest 2004;27:353-6.
21. Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc 1999;151:209-13.
22. Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasi J, Varela C, Sancho J. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998;83:2580-4.
23. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997;82:777-80.
24. Gullu S, Emral R, Asik M, Cesur M, Tonyukuk V. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest 2003;26:1198-202.
25. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93:233-41.
26. Goh VH. Breast tissues in transsexual women-a nonprostatic source of androgen up-regulated production of prostate-specific antigen. J Clin Endocrinol Metab 1999;84:313-5.
27. Yu H. Clinical implications of prostate-specific antigen in men and women. J Gend Specif Med 2000;53:45-8.
28. Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int J Cancer 2004;108:588-91.
29. Seliger E, Kaltwasser P, Ropke F. Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium: new diagnostic approaches. Zentralbl Gynakol 1998;120:72-5. [German].
30. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, et al. Expression of human prostate-specific glandular kallikrein protein (hK2) expression in the breast cancer cell line T47-D. Cancer Res 1997;57:2651-6.
31. Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000;59:1-14.
32. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
33. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
34. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999;20:348-55.
35. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997;75:579-88.
36. Katsaros D, Melegos DN, Diamandis EP. Prostate specific antigen production by breast tumors after induction with oral contraceptives. Clin Biochem 1998;31:285-8.
37. Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999;85:891-8.